Specialty Pharmacy

David D'Altorio, PharmD, senior vice president of health services at MedImpact Healthcare Systems, Inc, discusses how the ACA has impacted the specialty landscape.

Some patients with MS received a benefit from natalizumab involving the reduction of relapses and new MRI lesions.

Prescription drug use increased significantly among persons aged 40 to 64 years and among those age 65 and older.

People living in poorer areas less likely to receive screening.

The US Senate has launched a bipartisan investigation into prescription drug pricing, targeting Valeant, Turing Pharma, Retrophin, and Rodelis in particular.

Gilead's Genvoya is the first TAF-based regimen approved by the FDA.

Terms like revolutionary or miracle cause confusion for readers.

Biofilm proteins show promise in treatment of gastrointestinal disorders.

Nucala is for use with other asthma drugs for the maintenance of patients 12 years and older.

Liver disease experts suggest how to prioritize the treatment of different HCV patient groups.

Intensity modulated radiation therapy shows less intense lung toxicity for more tolerable chemotherapy.

Guidance addresses the development of clinical trials to test novel antiretroviral drugs for the treatment of HIV.

A 1961 Oklahoma Board of Pharmacy statute is just now causing tension between pharmacists and physicians.

Keytruda has already been approved for metastatic non-small cell lung cancer and metastatic melanoma.

Ryan Nolan, PharmD, MBA, CSP, clinical services manager at Diplomat, discusses ongoing lessons from the market reaction to high cost hepatitis C treatments.

There are currently no approved treatments for tenosynovial giant cell tumors.

Leading online and digital news source responds to recent news reports, distinguishes between high touch specialty pharmacies and organizations that offer products without other support important to those needing complex care.

Health application allows patients to report respiratory symptoms and peak flow measurements from COPD.

Nonadherence carries significant implications for stakeholders throughout the specialty space.

Medication waste may be more likely among patients who use mail-order pharmacies, rather than retail pharmacies.

Cancer microenvironment may hold the key to increasing immunotherapy drug efficacy.

With the high volume of cancer drugs available, determining the most effective combination is a significant hurdle.

Altering viral swarm may drive development of antibodies that could neutralize HIV strains.

Probiotics may offer a potential treatment for clostridium difficile infection.

Risk of death in patients with cardiovascular and respiratory conditions amplified in female patients with rheumatoid arthritis.

Drop in physical activity level linked to increased airflow obstruction.

Patients prescribed drugs for indications that the FDA has not approved face a 44% greater risk for adverse drug events.

A man went into a Rite Aid seeking treatment for diarrhea. Next thing he knew, he was detained at a medical center for 7 hours while he was tested for Ebola.

Multiple myeloma therapeutic spending forecast to his $22.4 billion by 2023.

Jon Hamrick, executive vice president, Biotech and Specialty Services at Therigy LLC, discusses methods to overcome the challenge of high out-of-pocket costs that can have a negative impact on patient medication adherence.